The Sanofi laboratory has developed a new vaccine once morest bronchiolitis. How effective is it? Will it be available this winter?
30% of children under 2 years old
Bronchiolitis affects nearly 30% of babies under 2 years old, according to the union of young generalists. Bronchiolitis is an acute respiratory viral infection. She causes a inflammation which leads to breathing difficulties with a strong cough and an wheezing and fast.
Soon a French vaccine?
The Sanofi laboratory has developed with AstraZeneca a vaccine for infants up to one year old. 2,300 children participated in studies clinics. The effectiveness is 80% once morest serious forms. Additionally, the vaccine is well tolerated and protects toddlers with just one injection.
Green light from Europe in November
The European Medicines Agency (EMA) should give its green light for marketing here November. However, this new Sanofi vaccine will not be marketed in France before thewinter 2023. Indeed, the French authorities will have to analyze the results of the clinical study and negotiate the price you vaccine.
Source : Syndicate of young general practitioners